Understanding how a specific protein helps repair DNA damage in cancer cells
Elucidating the role of DNAPKcs in chromosomal break end joining and clastogen resistance
['FUNDING_R01'] · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · NIH-10866510
This study is looking at a protein called DNAPKcs that helps cancer cells fix their broken DNA, and it aims to find ways to block this protein so that tumors become easier to treat with therapies like radiation, ultimately helping doctors create more tailored treatments for patients.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE (nih funded) |
| Locations | 1 site (DUARTE, UNITED STATES) |
| Trial ID | NIH-10866510 on ClinicalTrials.gov |
What this research studies
This research investigates the role of a protein called DNAPKcs in repairing chromosomal breaks in cancer cells, particularly how it interacts with other proteins involved in DNA repair. The study aims to develop inhibitors that can make tumors more sensitive to treatments like radiotherapy by disrupting the function of DNAPKcs. By identifying the conditions under which these inhibitors are most effective, the research seeks to create biomarkers that can predict how well a tumor will respond to treatment. This could lead to more personalized and effective cancer therapies for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with tumors that exhibit chromosomal breaks and may benefit from enhanced radiotherapy.
Not a fit: Patients with tumors that do not have chromosomal breaks or those who are not undergoing radiotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer treatments that enhance the effectiveness of radiotherapy for patients with specific tumor types.
How similar studies have performed: Other research has shown promise in using kinase inhibitors to enhance the effectiveness of cancer treatments, indicating that this approach may lead to significant advancements.
Where this research is happening
DUARTE, UNITED STATES
- BECKMAN RESEARCH INSTITUTE/CITY OF HOPE — DUARTE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: STARK, JEREMY MICHAEL — BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
- Study coordinator: STARK, JEREMY MICHAEL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Treatment